source
- FDA delays Leqembi decision; Artiva raises $300M; Pharvaris prices offering🗓️ FDA delays subcutaneous Leqembi decision: Originally slated for later this month, the decision date now falls on August 24, Biogen and Eisai said. The agency asked for more information from ...Endpoints · 2mo ago↗ source
- FDA to reevaluate spurned cell therapy; Under-the-skin Leqembi review extendedPierre Fabre claims to now be “aligned” with U.S. regulators on the path forward for a twice-rejected treatment. Elsewhere, Argenx swapped CEOs and Blackstone made a $250 million biotech investment.BioPharma Dive · 2mo ago↗ source
- Lilly, Gilead lead pharma’s M&A boomDeal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune disease drugs.